Drug intelligence / Profile preview

VXA-222

Development stage: Preclinical
Lead developer: VERAXA Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VXA-222 is a bispecific antibody-drug conjugate (BsADC) currently in the discovery phase of development by VERAXA Biotech. Designed for the treatment of solid tumors, VXA-222 leverages VERAXA's proprietary site-specific conjugation platform, which utilizes click chemistry to precisely attach cytotoxic payloads to bispecific antibodies. This dual-targeting approach is intended to enhance tumor selectivity and promote efficient internalization of the drug-linker complex, potentially improving the therapeutic index and overcoming resistance mechanisms often encountered with conventional monospecific ADCs.

Beyond the preview

Go deeper on VXA-222.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXA-222.

Explore the full profile